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Background: Patients over 80 years (octogenarians) are prone to bradycardia due to age-related alteration of the sinus node, AV node and 
conduction system. Therefore, the use of beta-blockers may be limited. Ivabradine has antianginal efficacy due to reduction of heart rate. The 
REDUCTION multicenter Study evaluated the antianginal efficacy of ivabradine in every day clinical practice. In this subgroup analysis, the efficacy 
and safety of ivabradine was evaluated in octogenarians.
Methods: 4954 patients were included in the REDUCTION Study for the treatment of stable angina pectoris with ivabradine. In this subgroup 
analysis 382 octogenarians were followed for 4 months. Patients were treated with ivabradine 2.5, 5 or 7.5 mg bid. After baseline evaluation 
consecutive visits were conducted after 1 and 4 months. Heart rate (HR), number of angina attacks, nitrate consumption, overall efficacy and 
tolerance according to the physicians judgement were evaluated. Baseline and follow-up observation values were compared.
Results: 382 octogenarians (83 ± 2.9 years) with stable angina pectoris were analyzed. 45% of the patients had undergone a previous PCI or 
CABG, 35% had a history of myocardial infarction. At baseline, mean HR was 82.8 ± 15.5 bpm and 81% of patients had at least one angina attack 
per week. A mean of 3.0 ± 4.6 angina attacks per week were reported and consumption of short-acting nitrates was 4.2 ± 5.1 units per week. After 
4 months of treatment, ivabradine reduced HR by 11.9 ± 12 bpm at a mean dose of 9.4 mg per day. The number of angina attacks was reduced by 
73% and nitrate consumption by 74%.
Four pts (1.0%) reported suspected adverse drug reactions (ADR). In one patient a syncope occurred. There was no symptomatic bradycardia 
reported. For 95% of patients physicians considered the efficacy of ivabradine as “very good/good”. For 99% of patients the tolerance was rated as 
“very good/good”.
Conclusion: The results demonstrate the efficacy of ivabradine in reducing heart rate, number of angina attacks and nitrate consumption in 
octogenarian patients. The treatment of angina pectoris with ivabradine was effective, safe and was very well tolerated without relevant bradycardia. 
